U.S. Markets closed

Takeda Pharmaceutical Company Limited (TKPHF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
51.380.00 (0.00%)
At close: 2:56PM EDT
People also watch
Full screen
Previous Close51.38
Bid0.00 x
Ask0.00 x
Day's Range0.00 - 0.00
52 Week Range
Avg. Volume1,493
Market Cap39.82B
PE Ratio (TTM)38.98
EPS (TTM)1.32
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters9 hours ago

    UPDATE 1-Seattle Genetics, Takeda lymphoma drug success fails to impress investors

    Seattle Genetics Inc and Japan's Takeda Pharmaceutical Co Ltd said on Monday that their drug met the main goal in a late-stage study of helping blood cancer patients live longer without their condition worsening. The study testing the combination as an initial treatment for advanced Hodgkin's lymphoma showed 82.1 percent lower risk of cancer progression in patients, compared with 77.2 percent in the control arm. The control arm used standard-of-care chemotherapy, ABVD, which combines adriamycin, bleomycin, vinblastine and dacarbazine drugs.

  • Reuterslast month

    Israel's BiomX raises $24 mln in private funding round

    BiomX, which is developing drugs using microbiome bacteria, said on Monday it raised $24 million in an early stage funding round led by OrbiMed, Jonhnson & Johnson Innovation and Takeda Ventures. Seventure ...

  • Reuters2 months ago

    U.S. FDA approves Takeda's lung cancer drug as 2nd-line treatment

    Japan's Takeda Pharmaceutical Co Ltd said on Friday that the U.S. Food and Drug Administration approved its lung cancer drug, almost three months after the company acquired the drug's developer, Ariad Pharmaceuticals Inc. The drug, Alunbrig, is approved as a second-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer, who have progressed on or are intolerant to Pfizer's crizotinib, the standard initial treatment for the disease. Alunbrig was approved under the FDA's accelerated approval program, which allows for quicker approval of drugs that fill an unmet medical need.